Analytical Data
-
Gene name
ARF6
- Application
-
Alternative Names
ADP ribosylation factor 6 ; ADP ribosylation factor protein 6; ADP-ribosylation factor 6; ARF6; ARF6_HUMAN; DKFZp564M0264; Small GTP binding protein ; Small GTPase
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P62330
-
Expression Region
1-175aa
-
Molecular Weight
36.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ARF6 (ADP-ribosylation factor 6) is a member of the ARF family of small GTPases, which plays a crucial role in intracellular trafficking, membrane dynamics, and cytoskeletal organization. The understanding of ARF6's biological functions has expanded significantly over the years, revealing its involvement in various cellular processes such as endocytosis, exocytosis, and the regulation of signaling pathways. Aberrant regulation of ARF6 has been implicated in several pathophysiological conditions, including cancer, neurodegenerative diseases, and cardiovascular disorders. As a pivotal regulator of membrane-cytoskeleton interactions and cellular morphology, ARF6 functions through its cycling between an active GTP-bound state and an inactive GDP-bound state, facilitating molecular interactions with diverse effector proteins. Recent advances in recombinant protein technology enable researchers to produce ARF6 in a controlled environment, allowing detailed studies of its functional properties and interactions at the molecular level. This research holds the potential to elucidate ARF6's role in health and disease, paving the way for targeted therapeutic strategies aimed at modulating its activity. Thus, the investigation of ARF6 recombinant protein represents a significant avenue for understanding fundamental cellular processes and developing innovative approaches to tackle diseases associated with its dysregulation.
